-
1
المؤلفون: Oliver W. Press, John O. Prior, Claudine Helg, Cristian Antonescu, Marek Kosinski, Nicolas Ketterer, Angelika Bischof Delaloye, Franz Buchegger
المصدر: Journal of Nuclear Medicine. 52:896-900
مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, medicine.medical_treatment, 131I-tositumomab, Antineoplastic Agents, Tositumomab, Refractory, Bone Marrow, hemic and lymphatic diseases, Internal medicine, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Radiometry, Bone Marrow Diseases, Aged, Chemotherapy, business.industry, Lymphoma, Non-Hodgkin, Remission Induction, Antibodies, Monoclonal, Middle Aged, Radioimmunotherapy, Antigens, CD20, Prognosis, medicine.disease, Recombinant Proteins, United States, Lymphoma, Indolent lymphoma, Europe, England, Drug Resistance, Neoplasm, Interferon Type I, Female, Rituximab, Neoplasm Recurrence, Local, Radiopharmaceuticals, business, Switzerland, Follow-Up Studies, medicine.drug